HPLC method development for fampridine using Analytical Quality by Design approach
Authors:
Open Access
- 13 May 2020
- journal article
- research article
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 70 (4) , 465-482
Abstract
Offering a systematic and multivariate analysis of the analytical procedure, development and validation of HPLC methods using Quality by Design approach are in the limelight of current research trends. A new, experimental design-aided HPLC method for fampridine was developed and preliminarily validated according to current in-force international guidelines for linearity, accuracy, robustness and precision. The method offers a high throughput sample analysis, with an elution time of 2.9 minutes, and signal detection without excipient interference performed at 262 nm. The method proved to be linear between 1–15 µg mL −1 ( R 2 = 0.9996). The mean recovery was found to be 98.7 ± 1.9 % in the tested range of 2.5–7.5 µg mL −1 . Low RSD values (< 1 %) were obtained for both model, intra- and inter-day precision. The limit of detection and limit of quantification were 0.24 and 0.78 µg mL −1 , resp. The method proved to be applicable for active substance assay in a pharmaceutical dosage form.Keywords
This publication has 22 references indexed in Scilit:
- Immunopathology of multiple sclerosisNature Reviews Immunology, 2015
- Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosisExpert Opinion on Drug Metabolism & Toxicology, 2014
- Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosisCurrent Medical Research and Opinion, 2013
- Formulation optimization of itraconazole loaded PEGylated liposomes for parenteral administration by using design of experimentsInternational Journal of Pharmaceutics, 2013
- Formulation and optimization of fenofibrate lipospheres using Taguchi’s experimental designActa Pharmaceutica, 2013
- A stability indicating simultaneous dual wavelength UV–HPLC method for the determination of potential impurities in fampridine active pharmaceutical ingredientJournal of Pharmaceutical and Biomedical Analysis, 2012
- A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAnnals of Neurology, 2010
- Single‐Dose Pharmacokinetics of Sustained‐Release Fampridine (Fampridine‐SR) in Healthy Volunteers and Adults With Renal ImpairmentThe Journal of Clinical Pharmacology, 2010
- Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialThe Lancet, 2009
- Molecular Diversity of K+ ChannelsAnnals of the New York Academy of Sciences, 1999